CCAB CEO highlights the high contribution of academic research in drug development
In June 2015, CCAB CEO Dr. Sachdev Sidhu was interviewed for the CBC news item “Spotlight on Alexion’s pricing of rare-disease drug Soliris” as an expert in the process of developing antibody-based drugs. Dr. Sidhu highlighted the fact that a large part of the research required to develop a drug is performed in academic labs funded by public money, and that the real cost of drug development should therefore be more transparent. The news item discussed how the high cost of the antibody drug “Soliris” is based on what the market can bear, rather than on the actual cost of developing the drug. The story was also broadcast on CBC’s “The National”.